CareDx(US:CDNA)2025-11-04 21:30Financial Performance - Total revenue grew by 21% year-over-year, reaching $100.1 million in Q3 2025[15,47] - Testing Services revenue increased by 19% year-over-year, totaling $72.2 million in Q3 2025[22,47] - Patient & Digital Solutions revenue grew by 30% year-over-year, reaching $15.4 million in Q3 2025[41,47] - Adjusted EBITDA increased significantly by 122% year-over-year, reaching $15.3 million in Q3 2025[15,51] - The company raised revenue guidance for FY 2025 to a range of $372 million to $376 million[20] - The company raised adjusted EBITDA guidance for FY 2025 to a range of $35 million to $39 million[20] - Corporate Free Cash Flow increased by 233% year-over-year, reaching $36.1 million in Q3 2025[54] - Non-GAAP gross margin improved by 190 basis points year-over-year, reaching 71% in Q3 2025[49,61] Operational Highlights - Testing volume grew by 13% year-over-year, reaching 50.3K in Q3 2025[15,22] - The company launched HistoMap Kidney, a tissue-based molecular test[23]